The number-one challenge facing the biopharmaceutical industry today is public distrust, dwarfing concerns about regulatory obstacles or the sheer difficulty of the science required to develop drugs, a survey of STAT Plus subscribers shows.

Much of the public’s poor opinion of biopharma stems from runaway drug price hikes, and survey respondents had a lot to say about strategies being pursued in Washington to corral these costs. They give high marks to the tax law and brush off any concern about import tariffs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This is an annoying story. When reporting on survey results it’s pretty common to actually show the results, in the form of graphs and tables for each question. In this story, we are at the mercy of qualitative interpretation.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy